Skip to main navigation Skip to search Skip to main content

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

Research output: Contribution to journalArticleResearchpeer-review

Filter
Finished

Search results